
Acumen Pharmaceuticals Inc
NASDAQ:ABOS

Intrinsic Value
The intrinsic value of one
ABOS
stock under the Base Case scenario is
3.34
USD.
Compared to the current market price of 1.07 USD,
Acumen Pharmaceuticals Inc
is
Undervalued by 68%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Acumen Pharmaceuticals Inc
Fundamental Analysis


Revenue & Expenses Breakdown
Acumen Pharmaceuticals Inc
Balance Sheet Decomposition
Acumen Pharmaceuticals Inc
Current Assets | 154.9m |
Cash & Short-Term Investments | 149.1m |
Receivables | 376k |
Other Current Assets | 5.4m |
Non-Current Assets | 49.5m |
Long-Term Investments | 48.8m |
PP&E | 373k |
Other Non-Current Assets | 363k |
Free Cash Flow Analysis
Acumen Pharmaceuticals Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Acumen Pharmaceuticals Inc
Revenue
|
0
USD
|
Operating Expenses
|
-126.6m
USD
|
Operating Income
|
-126.6m
USD
|
Other Expenses
|
10.4m
USD
|
Net Income
|
-116.3m
USD
|
ABOS Profitability Score
Profitability Due Diligence
Acumen Pharmaceuticals Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

Score
Acumen Pharmaceuticals Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.
ABOS Solvency Score
Solvency Due Diligence
Acumen Pharmaceuticals Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.

Score
Acumen Pharmaceuticals Inc's solvency score is 54/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ABOS Price Targets Summary
Acumen Pharmaceuticals Inc
Dividends
Current shareholder yield for ABOS is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
ABOS
stock under the Base Case scenario is
3.34
USD.
Compared to the current market price of 1.07 USD,
Acumen Pharmaceuticals Inc
is
Undervalued by 68%.